---
layout: default
title: Activated Charcoal Anemone Pulsatilla Calcium Fluo
parent: 僅模型預測 (L5)
nav_order: 181
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Anemone Pulsatilla Calcium Fluo
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Complex (Homeopathic Preparation): No Repurposing Prediction Available

## One-Sentence Summary

This submission covers a nine-ingredient combination product—including Activated Charcoal, Anemone Pulsatilla, Lachesis Muta Venom, and Lycopodium Clavatum Spore—whose constituents are characteristic of classical homeopathic formulations.
The TxGNN model was **unable to generate any repurposing prediction** for this combination, as the product has no DrugBank identifier, no documented approved indication, and no mappable drug node in the knowledge graph.
With **zero clinical trials** and **zero publications** linked to any repurposing direction, this candidate cannot be meaningfully evaluated under the current pipeline.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no approved indication on record) |
| Predicted New Indication | None |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no model output generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Was Generated

TxGNN requires a single, DrugBank-mapped active pharmaceutical ingredient and at least one approved indication as entry points into the knowledge graph. This submission fails both requirements, for three compounding reasons.

**Nature of the formulation.** Six of the nine listed components — Anemone Pulsatilla, Calcium Fluoride, Claviceps Purpurea Sclerotium, Delphinium Staphisagria Seed, Lachesis Muta Venom, and Lycopodium Clavatum Spore — are established classical homeopathic remedies, typically administered in extreme dilutions (e.g., 6C–30C) where no original molecule is expected to remain. The remaining three components (Activated Charcoal, Hamamelis Virginiana, Zinc) do have pharmacological profiles individually, but their roles and concentrations within this specific combination are not defined in any retrieved dataset.

**No DrugBank anchor.** The pipeline returned `drugbank_id: null` and `query_status: not_found` for the compound string. Without a matched DrugBank node, TxGNN cannot compute any drug–disease edge score, and the predicted indications array is empty.

**No approved indication.** Because the product is not marketed and has no license history in any queried jurisdiction, there is no seed indication from which mechanistic similarity to other diseases could be derived.

In short, this is not a pipeline failure — it is a structurally correct "no-prediction" outcome for a submission that sits outside the boundary conditions of conventional drug repurposing methodology.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This product cannot advance through the TxGNN repurposing pipeline in its current form. The combination of zero DrugBank mapping, zero approved indications, zero market presence, and zero model predictions means there is no evidence foundation on which any repurposing recommendation could be responsibly built.

**To proceed, the following is needed:**

- **Clarify regulatory classification**: Determine whether this product is registered as a homeopathic preparation, a dietary supplement, or a conventional drug. If homeopathic, standard drug repurposing methodology does not apply; a separate evidence framework would be required.
- **Identify primary active ingredient(s)**: If any single constituent (e.g., Activated Charcoal, Zinc, Hamamelis Virginiana) is intended as the pharmacologically active agent, submit that ingredient individually for TxGNN analysis.
- **Obtain product monograph or package insert**: Resolve Data Gap DG001 (Blocking) — no safety warnings, contraindications, or labeled indication can be confirmed without the official prescribing document.
- **Retrieve mechanism of action data**: Resolve Data Gap DG002 (High) — DrugBank API queries for individual components (especially Activated Charcoal and Zinc) should be attempted separately to recover partial MOA information.
- **Confirm jurisdiction and approval status**: US FDA, EMA, and other major regulatory databases should be searched by brand name rather than by the full INN string, as multi-ingredient homeopathic products are often registered under proprietary names.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

